

SUPPLEMENTARY
MASTER OF PHARMACY (M. PHARM.) (CBCS-2019 COURSE)
M.Pharm. Sem-II REGULATORY AFFAIRS :SUMMER- 2022
SUBJECT : REGULATORY ASPECTS OF HERBAL & BIOLOGICALS

Day : Friday

Time : 10:00 AM-01:00 PM

Date : 16-09-2022

S-20779-2022

Max. Marks : 75

N.B.:

- 1) Question **1** and **5** are **COMPULSORY**. Out of remaining questions answer **ANY TWO** from each section
 - 2) Answers to both sections should be written in **SEPARATE** answer books.
 - 3) Figures to the **RIGHT** indicate **FULL** marks.
-

SECTION-I

- Q.1** Elaborate On Plasma Master File requirements in EU **(08)**
- Q.2** Explain USFDA's approach suggested for development of biosimilars. Add an elaborate note on analytical similarity demonstration for biosimilars in USFDA. **(15)**
- Q.3** Discuss preclinical and clinical data requirements for registration of a biosimilar product in India. **(15)**
- Q.4** Write notes **ANY TWO** of the following: **(15)**
- a) Biosimilar product labelling requirements in EU
 - b) TSE/BSE regulations in EU
 - c) Differentiate between generics and biosimilars

SECTION-II

- Q.5** Discuss USFDA's principles for vaccine development. **(07)**
- Q.6** Elaborate on Dietary Supplements regulations in USA. **(15)**
- Q.7** Write about EU CTD format for herbal drug preparations. **(15)**
- Q.8** Write notes **ANY TWO** of the following: **(15)**
- a) INH and ISBT
 - b) Blood bank requirements in India
 - c) ASU drug regulations in India

* * * * *